Aarti Pharmalabs Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The inspection concluded on 27 March 2026, following which the company received a Form 483 with one observation. According to the company, the observation is procedural in nature.

The company further stated that it will submit its corrective and preventive action (CAPA) plan along with compliance within the stipulated timeline prescribed by the US FDA.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.

The company reported a 35.2% decline in consolidated net profit to Rs 47.96 crore, despite a 19.6% decline in revenue from operations to Rs 432.27 crore in Q3 FY26 compared with Q3 FY25.

The counter slipped 1.99% to Rs 597 on the BSE.

Powered by Capital Market - Live News

According to the company, a minor leakage occurred while loading dimethyl sulphate, an industrial chemical, into a tanker. The leak was promptly contained and cleared, and there was no loss of life or damage to property.

As a precautionary measure, 22 workers were admitted to a nearby hospital for observation, of whom more than half have already been discharged.

The company informed the local police station, following which a First Information Report (FIR) was registered. An investigation into the incident is currently underway, and the company said it is fully cooperating with the authorities.

Aarti Pharmalabs added that normal operations at the plant were safely restored within 24 hours of the incident.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.

The company reported a 35.2% decline in consolidated net profit to Rs 47.96 crore, despite a 19.6% decline in revenue from operations to Rs 432.27 crore in Q3 FY26 compared with Q3 FY25.

The counter advanced 2.49% to Rs 631.95 on the BSE.

Powered by Capital Market - Live News

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 9 February 2026, inter alia, have recommended the interim dividend of Rs 1.5 per equity Share (i.e. 30%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Aarti Pharmalabs declined 35.18% to Rs 47.96 crore in the quarter ended December 2025 as against Rs 73.99 crore during the previous quarter ended December 2024. Sales declined 19.62% to Rs 432.27 crore in the quarter ended December 2025 as against Rs 537.78 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News